Latest News and Press Releases

Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an...

ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe...

ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for første halvår (Q2) af 2025 om morgenen torsdag den 21. august 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og...

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning on Thursday, 21 August 2025. Later on the same day, the company will host a presentation for...

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret. Omsætningen forventes nu at stige med 12-14% i lokale valutaer (mod tidligere:...

Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue is now expected to grow by 12-14% in local currencies (previously...

ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in...

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at det britiske Medicines and Healthcare Products Regulatory Agency (MHRA) har godkendt EURneffy® 2 mg til behandling af anafylaksi hos...

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for...

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely...